一項最新研究發現，采用手術治療癥狀性子宮纖維瘤，并發癥要比栓塞治療要少，但是平均住院時間較長。

Glasgow(UK)大學和愛丁堡大學醫學院(UK)研究人員將子宮纖維瘤的婦女，按照2:1的比例隨機分配，患者接受子宮動脈栓塞(UAE)治療，也就是將纖維瘤的血液供應阻斷，或者接受手術治療，結果有106例接受UAE手術而51例接受手術治療(43例子宮切除，8例肌神經切除)。這項研究的主要預后指標濕1年后隨訪的生命質量，通過問卷調查進行測量，即醫療預后研究36項短表格一般健康調查(SF-36)。

結果顯示在1年之后，手術組的癥狀評分在總體上優于UAE組。在第1年13例UAE治療婦女出現不良癥狀事件(12%)，而手術組有10例(20%)。10例UAE患者需要再次治療，或者在此UAE治療或者子宮切除。除此之外，在1年之后，UAE組中有14例(13%)需要在此入院，3例出現重大不良事件，11例由于初次UAE不成功而需要再次治療。該研究結果發表在2007年1月25日的《新英格蘭醫學期刊》之上。

Surgery Versus Embolization in Treating Fibroids
 
A new study has found that surgery for the treatment of symptomatic uterine fibroids results in fewer complications than embolization, but requires on average a significantly longer hospital stay.

Researchers of the University of Glasgow (UK) and the University of Edinburgh Medical School (UK) randomly assigned women suffering from uterine fibroids in a 2:1 ratio to undergo either uterine-artery embolization (UAE)--where the blood supply to the fibroids is blocked--or surgery, with 106 patients undergoing UAE and 51 undergoing surgery (43 hysterectomies and eight myomectomies). The primary outcome of the study was quality of life at one year follow-up, as measured by a questionnaire known as the medical outcomes study 36-item short-form General Health Survey (SF-36).

The results showed that after 1 year, the symptom scores in the surgical group were on the whole better than the UAE group. Within the first year period 13 of the UAE women had adverse symptom events (12%) compared with 10 in the surgery group (20%). Ten of the UAE patients needed a repeat treatment, either another UAE or hysterectomy. Additionally, after the first year, 14 women in the UAE group (13%) needed to be re-admitted to hospital, three for major adverse events and 11 for repeat treatment because the original UAE had not been successful. The results are published in the January 25, 2007, edition from The New England Journal of Medicine.